Gunnar Mattson

Gunnar Mattson

Auto-generated profile, based on publicly available information

Gunnar Mattson

Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, Md

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Pediatric Research
Verified
Journal Article
Closed access
COChin Siang Ong
Chin Siang Ong
PYPooja Yesantharao
Pooja Yesantharao
CHChen Yu Huang
Chen Yu Huang
GMGunnar Mattson
Gunnar Mattson
JBJoseph Boktor
Joseph Boktor
NHNarutoshi Hibino
Narutoshi Hibino

3 September 2019 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
EYEnoch Yeung
Enoch Yeung
TFTakuma Fukunishi
Takuma Fukunishi
YBYang Bai
Yang Bai
DBDjahida Bedja
Djahida Bedja
IPIsaree Pitaktong
Isaree Pitaktong
NHNarutoshi Hibino
Narutoshi Hibino

1 March 2018 in Biotechnology Advances
Verified
Journal Article
Closed access
COChin Siang Ong
Chin Siang Ong
XZXun Zhou
Xun Zhou
JHJingnan Han
Jingnan Han
CHChen Yu Huang
Chen Yu Huang
ANAndrew Nashed
Andrew Nashed
NHNarutoshi Hibino
Narutoshi Hibino

22 November 2019 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
TFTakuma Fukunishi
Takuma Fukunishi
COChin Siang Ong
Chin Siang Ong
PYPooja Yesantharao
Pooja Yesantharao
CBCameron A. Best
Cameron A. Best
TYTai Yi
Tai Yi
NHNarutoshi Hibino
Narutoshi Hibino

1 February 2020 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
IPIsaree Pitaktong
Isaree Pitaktong
CLCecillia Lui
Cecillia Lui
JLJustin Lowenthal
Justin Lowenthal
GMGunnar Mattson
Gunnar Mattson
WJWei-Hung Jung
Wei-Hung Jung
NHNarutoshi Hibino
Narutoshi Hibino
Introduction: A key obstacle in the creation of engineered cardiac tissues of clinically relevant sizes is limited diffusion of oxygen and nutrients. Thus, there is a need for organized vascularization within a three-dimensional (3D) tissue environment. Human induced pluripotent stem cell (hiPSC)-derived early vascular cells (EVCs) have shown to improve organization of vascular networks within hydrogels. We hypothesize that introduction of EVCs into 3D microtissue spheroids will lead to increased microvascular formation and improve spheroid formation. Methods: HiPSC-derived cardiomyocytes (CMs) were cocultured with human adult ventricular cardiac fibroblasts (FB) and either human umbilical vein endothelial cells (HUVECs) or hiPSC-derived EVCs for 72 h to form mixed cell spheroids. Three different groups of cell ratios were tested: Group 1 (control) consisted of CM:FB:HUVEC 70:15:15, Group 2 consisted of CM:FB:EVC 70:15:15, and Group 3 consisted of CM:FB:EVC 40:15:45. Vascularization, cell distribution, and cardiac function were investigated. Results: Improved microvasculature was found in EVC spheroids with new morphologies of endothelial organization not found in Group 1 spheroids. CMs were found in a core-shell type distribution in Group 1 spheroids, but more uniformly distributed in EVC spheroids. Contraction rate increased into Group 2 spheroids compared to Group 1 spheroids. Conclusion: The triculture of CM, FB, and EVC within a multicellular cardiac spheroid promotes microvascular formation and cardiac spheroid contraction.

18 March 2020 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
AAAbela Mpobela Agnarson
Abela Mpobela Agnarson
AWAbeda Williams
Abeda Williams
CKChrispin Kambili
Chrispin Kambili
GMGunnar Mattson
Gunnar Mattson
LMLaurent Metz
Laurent Metz
Background: Bedaquiline-containing regimens have demonstrated improved outcomes over injectable-containing regimens in the long-term treatment of multidrug-resistant tuberculosis (MDR-TB). Recently, the World Health Organization (WHO) recommended replacing injectables in the standard short-course regimen (SCR) with a bedaquiline-containing regimen. The South African national TB program similarly recommends a bedaquiline-containing regimen. Here, we investigated the cost-effectiveness of a bedaquiline-containing SCR versus an injectable-containing SCR for the treatment of MDR-TB in South Africa. Methods: A Markov model was adapted to simulate the incidence of active patients with MDR-TB. Patients could transition through eight health states: active MDR-TB, culture conversion, cure, follow-up loss, secondary MDR-TB, extensively DR-TB, end-of-life care, and death. A 5% discount was assumed on costs and outcomes. Health outcomes were expressed as disability-adjusted life years (DALYs). Results: Over a 10-year time horizon, a bedaquiline-containing SCR dominated an injectable-containing SCR, with an incremental saving of US $982 per DALY averted. A bedaquiline-containing SCR was associated with lower total costs versus an injectable-containing SCR (US $597 versus $657 million), of which US $3.2 versus $21.9 million was attributed to adverse event management. Conclusions: Replacing an injectable-containing SCR with a bedaquiline-containing SCR is cost-effective, offering a cost-saving alternative with improved patient outcomes for MDR-TB.